Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
Therapeutic Advances in Gastroenterology · 2024-01 · 17
DOI: 10.1177/17562848241290636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 16.10.2024. Verfasst von Péter Bacsur und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Emberi Eroforrások Minisztériuma, Szegedi Tudományegyetem.
Abstract (Originalsprache)
Background
The usability of subcutaneous vedolizumab (s.c. VDZ) treatment in inflammatory bowel diseases (IBD; ulcerative colitis (UC), Crohn’s disease (CD)) has been proven via clinical trials while real-world data collection is ongoing.
Objectives
Our study evaluates the effectiveness, safety, patients’ preferences, and psychological factors associated with s.c. VDZ treatment, after switching from intravenous (i.v.) formulation.
Design
Prospective, multicenter cohort study including IBD patients switching from i.v. VDZ to s.c. treatment and were evaluated over 52 weeks.
Methods
Serum VDZ levels and C-reactive protein (CRP) were measured at the baseline and w52. At w12, a questionnaire on the patient’s satisfaction and psychological characteristics was administered. The primary outcome was the drug persistence rate (cessation was due to loss of response (LOR), adverse events, patient request, and other causes) at w52, while the secondary outcomes were the changes in the clinical corticosteroid-free remission (CSFR) and biochemical remission (BR; CRP ⩽ 5 mg/L) rates, safety issues, serum drug levels, patients’ preferences, and psychological features.
Results
In total, 70 IBD patients were evaluated (32 CD patients, 38 UC patients; male/female ratio: 41.4%; median age: 43.2 years). In the CD group, 81.3% were in CSFR and 65.6% were in BR, while in the UC group, 71.7% were in CSFR and 69.4% were in BR. Overall, 17.1% of the patients ceased s.c. VDZ treatment after a median of 26.2 (interquartile range 20–47) weeks. LOR was registered in 3/12 ceased patients. In addition, CSFR and BR rates were stable, while serum VDZ levels increased by w52 ( p < 0.001).
Conclusion
The transition from i.v. to s.c. VDZ treatment was effective, the overall persistence rate was associated with high serum drug levels, and no novel safety issues were reported. Although s.c. administration after induction can save resources, some patients still insisted on i.v. VDZ treatment, due to its proven formulation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
- HCEMM-USZ Translational Colorectal Research Group, Szeged, Hungary.
- Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary.
- Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
- Institute of Laboratory Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
- Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada.
ORCID-Profile: Péter Bacsur, Tamás Resál, Patrícia Sarlós, Bernadett Farkas, Anna Fábián, Renáta Bor, Péter L Lakatos, Tamás Molnár
Förderung
- Horizon 2020 Framework Programme
- Emberi Eroforrások Minisztériuma
- Szegedi Tudományegyetem
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem
Zitieren
APA
Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L., & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic Advances in Gastroenterology, 17. https://doi.org/10.1177/17562848241290636
Vancouver
Bacsur P, Resál T, Sarlós P, Iliás Á, Dalma Sümegi L, Kata D, et al. Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic Advances in Gastroenterology. 2024;17. doi:10.1177/17562848241290636
BibTeX
@article{Bacsur2024,
author = {Bacsur, Péter and Resál, Tamás and Sarlós, Patrícia and Iliás, Ákos and Dalma Sümegi, Liza and Kata, Diána and Dávid, Anett and Farkas, Bernadett and Ivány, Emese and Bálint, Anita and Bősze, Zsófia and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Afif, Waqqas and Bessissow, Talat and Farkas, Klaudia and Lakatos, Péter L and Molnár, Tamás},
title = {Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases},
journal = {Therapeutic Advances in Gastroenterology},
year = {2024},
volume = {17},
doi = {10.1177/17562848241290636}
}
EUVIMED